Español 
Deutsch 
Français 
MSCI World Index (MSC)
NASDAQ Composite (NASDAQ)
FTSE China A50 Index (FGI)
STOXX Europe 600 (SIX)
Nikkei 300 (OSA)
NIFTY 50 (NSE)
DAX Performance Index (XETRA)
FTSE 100 (FGI)
CAC 40 (EURONEXT)
Galera Therapeutics, Inc. (GRTX)
USD16.39
-0.17 (-1.02%)
US OTC Healthcare Biotechnology
Address
2 West Liberty Boulevard 19355
Malvern, PA, US
Malvern, PA, US
CEO
J. Mel Sorensen
Website
galeratx.com
IPO
2019-11-07
CIK 1563577 ISIN US36338D1081
Description
Galera Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company, specializing in the creation and commercialization of therapies aimed at revolutionizing cancer radiotherapy. Its lead investigational drug, avasopasem manganese (GC4419), functions as a small molecule superoxide dismutase mimetic. This compound has successfully completed a Phase III clinical trial targeting severe oral mucositis induced by radiation therapy in head and neck cancer (HNC) patients. Furthermore, GC4419 is currently undergoing Phase IIa clinical trials for radiotherapy-induced esophagitis in lung cancer patients, as well as for HNC patients undergoing standard-of-care radiation treatment. The company is also progressing with GC4711, another superoxide dismutase mimetic candidate, which is in a Phase I/II clinical trial. This trial evaluates its combination with stereotactic body radiation therapy (SBRT) for individuals diagnosed with non-small cell lung cancer and locally advanced pancreatic cancer. Galera Therapeutics was founded in 2012 and maintains its headquarters in Malvern, Pennsylvania.
Market Cap & Enterprise Value
Merger & Acquisition History
No mergers or acquisitions recorded for this company.
Technical Outlook
Loading outlook…
Loading forecast...
Signal Summary
Loading…
| Indicator | 1D | 1W | 2W | 3W | 1M |
|---|
Each column is computed on that timeframe's candles (1D = daily, 1W ≈ weekly, 1M ≈ monthly), not on the same last day. ▲ bullish · ▼ bearish · — neutral. The Net row counts signals per column; hover any cell (or the indicator name) to see the exact rule behind it.
Day Score & sub-scores
Statistical fingerprint & regime detail
Conditional historical analysis
Customize analysis (advanced)
Indicative levels generated algorithmically. Not financial advice.
Risk Profile
Loading risk profile…
Price Chart
USD16.39
-0.17 (-1.02%)
Loading historical data…
Volume Profile
Loading…
Liquidity & share structure
Average Volume
314.0K
Beta
2.61
Float Shares
45.63M
Free Float %
60.1%
Price Performance
| 1D | 5D | 1M | 3M | 6M | YTD | 1Y | 3Y | 5Y | 10Y | Max |
|---|---|---|---|---|---|---|---|---|---|---|
| +0.00% | +0.00% | +12.61% | +371.70% | +344.44% | +354.55% | +316.67% | -96.92% | -98.74% | -99.17% | -99.17% |
Rolling Volatility
Loading…
Drawdown
Loading…
Relative Strength
Loading…
Monthly Returns Heatmap
From
To
Loading…
Annual Monthly Returns
Loading…
Daily Returns Distribution
Loading histogram data…
Revenue flow
Revenue by geography
Revenue by segment
From
To
Revenue composition
From
To
By product
By geography
Financial Statements
Select metrics from the tables below to build your comparison.
Income Statement
Balance Sheet
Cash Flow Statement
Key Metrics
Financial Ratios
Employees
Financial Growth (CAGR)
Market Data
Analyst Consensus (9 ratings, all time)
Buy
Price Targets & DCF
Current price
16.39
DCF (Unlevered)
0.06
-99.6%
DCF (Levered)
0.06
-99.6%
DCF figures are point estimates: small changes in growth or discount-rate assumptions move them materially. Read them as a reference, not a precise target.
Ratings Trend (MoM)
0% Bullish
| Rating | 2024-11 | Change |
|---|---|---|
| Strong Buy | 0 | 0 |
| Buy | 0 | 0 |
| Hold | 1 | 0 |
| Sell | 0 | 0 |
| Strong Sell | 0 | 0 |
Quality scores
Altman Z-Score
-68.26
Distress
Piotroski F-Score
2 / 9
Weak
MOAT Score
2 / 10
No MOAT
Composite Rating
A
Overall Score
4 / 5
High
DCF Score
3 / 5
Medium
ROE Score
5 / 5
High
ROA Score
5 / 5
High
D/E Score
1 / 5
Low
P/E Score
3 / 5
Medium
P/Book Score
5 / 5
High
Operational MOAT
✗ Below peers
-
Revenue growth Biotechnology: +1.6%—
-
EPS growth Biotechnology: +29.7%+531.4% ★ Q1'26: +44.0% (vs Q1'25)
-
FCF margin FCF growth · Biotechnology: +16.2%—
-
EBIT margin Biotechnology: +0.0%—
-
ROIC Biotechnology: -16.1%-3,433.0% Q1'26: +1,387.8% (vs Q1'25)
-
Share dilution Biotechnology: -3.4%+80.3% Q1'26: +80.5% (vs Q1'25)
-
Debt / EBITDA Net debt/EBITDA · Biotechnology: 0.16×0.00× Q1'26: 0.00× (vs Q1'25)
Valuation Multiples
From
To
Price Forecast (3Y)
From
To
Theoretical Return — If Invested Today
* These projections are based on analyst consensus estimates and user-defined valuation multiples. This table is for informational purposes only and does not constitute a recommendation to buy or sell any security. Past performance is not indicative of future results.
Consensus Estimates
| Metric |
Dec 2024 actual |
Dec 2025 actual |
|---|---|---|
| Revenue |
—
est: 50.00M (-100.0%)
|
—
|
| EBITDA |
-20.16M
|
-6.04M
|
| EBIT |
-19.16M
|
-6.04M
|
| Net Income |
-18.96M
est: -8.08M (-134.7%)
|
149.05M
est: -76.89M (+293.8%)
|
| SGA |
11.00M
|
5.69M
|
| EPS |
-0.35
est: -0.08 (-326.8%)
|
1.51
est: -0.78 (+293.4%)
|
Historical Ratings (3M)
| Date | Rating | Overall | DCF | ROE | ROA | D/E | P/E | P/B |
|---|---|---|---|---|---|---|---|---|
| 2026-05-11 | A | 4/5 | 3/5 | 5/5 | 5/5 | 1/5 | 3/5 | 5/5 |
| 2026-05-08 | A | 4/5 | 3/5 | 5/5 | 5/5 | 1/5 | 4/5 | 5/5 |
| 2026-05-07 | A | 4/5 | 3/5 | 5/5 | 5/5 | 1/5 | 4/5 | 5/5 |
| 2026-05-06 | A | 4/5 | 3/5 | 5/5 | 5/5 | 1/5 | 4/5 | 5/5 |
| 2026-05-05 | A | 4/5 | 3/5 | 5/5 | 5/5 | 1/5 | 4/5 | 5/5 |
| 2026-05-04 | A | 4/5 | 3/5 | 5/5 | 5/5 | 1/5 | 4/5 | 5/5 |
| 2026-05-01 | A | 4/5 | 3/5 | 5/5 | 5/5 | 1/5 | 4/5 | 5/5 |
| 2026-04-30 | A | 4/5 | 3/5 | 5/5 | 5/5 | 1/5 | 4/5 | 5/5 |
| 2026-04-29 | A | 4/5 | 3/5 | 5/5 | 5/5 | 1/5 | 4/5 | 5/5 |
| 2026-04-28 | A | 4/5 | 3/5 | 5/5 | 5/5 | 1/5 | 4/5 | 5/5 |
| 2026-04-27 | A | 4/5 | 3/5 | 5/5 | 5/5 | 1/5 | 4/5 | 5/5 |
| 2026-04-24 | A | 4/5 | 3/5 | 5/5 | 5/5 | 1/5 | 4/5 | 5/5 |
| 2026-04-23 | A | 4/5 | 3/5 | 5/5 | 5/5 | 1/5 | 4/5 | 5/5 |
| 2026-04-22 | A | 4/5 | 3/5 | 5/5 | 5/5 | 1/5 | 4/5 | 5/5 |
| 2026-04-21 | A+ | 4/5 | 4/5 | 5/5 | 5/5 | 1/5 | 4/5 | 5/5 |
| 2026-04-20 | A+ | 4/5 | 4/5 | 5/5 | 5/5 | 1/5 | 4/5 | 5/5 |
| 2026-04-17 | A | 4/5 | 4/5 | 5/5 | 5/5 | 1/5 | 3/5 | 5/5 |
| 2026-04-16 | A | 4/5 | 4/5 | 5/5 | 5/5 | 1/5 | 3/5 | 5/5 |
Owner Earnings
Owner's Earnings (history)
Owner's Earnings history not available.
Owner alignment
Owner's Earnings TTM
—
OE per share TTM
—
Owner's Yield
—
Maintenance CapEx ratio
—
Maint CapEx / Avg PPE
—
Ownership Overview
Ownership breakdown
At a glance
Institutional holders
1
Total invested
4.00
Insider transactions (90d)
0
Beneficial owners (>5%)
25
Beneficial owners (>5%)
| # | Reporting person | Amount owned | % of class | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Type | Citizenship | Filing date | SEC filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Yair Schneid | 7.11M | 13.07% | 7.11M | — | 7.11M | — | IN | USA | 2024-01-17 | ↗ |
| 2 | Alpha Pharma Investments LLC | 5.93M | 10.90% | — | 5.93M | — | 5.93M | CO | Delaware | 2024-05-16 | ↗ |
| 3 | Rochel Soffer | 5.93M | 10.90% | — | 5.93M | — | 5.93M | IN | USA | 2024-05-16 | ↗ |
| 4 | Altamont Pharmaceutical Holdings, LLC | 5.28M | 12.02% | — | 5.28M | — | — | OO | Texas | 2023-11-13 | ↗ |
| 5 | Mark Pearson | 5.28M | 12.02% | — | 5.28M | — | — | IN | Texas | 2023-11-13 | ↗ |
| 6 | Company, L.P. | 2.92M | 4.99% | — | 2.92M | — | — | PN | Delaware | 2023-02-28 | ↗ |
| 7 | Deerfield Mgmt, L.P. | 2.92M | 4.99% | — | 2.92M | — | — | PN | Delaware | 2023-02-28 | ↗ |
| 8 | Deerfield Partners, L.P. | 2.92M | 4.99% | — | 2.92M | — | — | PN | Delaware | 2023-02-28 | ↗ |
| 9 | James E. Flynn | 2.92M | 4.99% | — | 2.92M | — | — | IN | United States | 2023-02-28 | ↗ |
| 10 | Blackstone Group Management L.L.C. | 2.27M | 7.80% | 2.27M | — | 2.27M | — | OO | — | 2023-02-09 | ↗ |
| 11 | Blackstone Inc. | 2.27M | 7.80% | 2.27M | — | 2.27M | 11.00 | CO | — | 2023-02-09 | ↗ |
| 12 | Stephen A. Schwarzman | 2.27M | 7.80% | 2.27M | — | 2.27M | — | IN | — | 2023-02-09 | ↗ |
| 13 | Blackstone Clarus GP L.L.C. | 2.23M | 7.70% | 2.23M | — | 2.23M | — | OO | — | 2023-02-09 | ↗ |
| 14 | Blackstone Clarus GP L.P. | 2.23M | 7.70% | 2.23M | — | 2.23M | — | PN | — | 2023-02-09 | ↗ |
| 15 | Blackstone Holdings I L.P. | 2.23M | 7.70% | 2.23M | — | 2.23M | — | PN | — | 2023-02-09 | ↗ |
| 16 | Blackstone Holdings I/II GP L.L.C. | 2.23M | 7.70% | 2.23M | — | 2.23M | — | OO | — | 2023-02-09 | ↗ |
| 17 | Clarus IV GP, L.P. | 2.23M | 7.70% | 2.23M | — | 2.23M | — | PN | — | 2023-02-09 | ↗ |
| 18 | Jérôme G. Pfund | 1.67M | 5.80% | 689.2K | — | 1.67M | — | IN | Swiss | 2023-02-13 | ↗ |
| 19 | Michael L. Sjöström | 1.67M | 5.80% | 689.2K | — | 1.67M | — | IN | Canada | 2023-02-13 | ↗ |
| 20 | Sectoral Asset Management Inc | 1.67M | 5.80% | 689.2K | — | 1.67M | — | IA | Canada | 2023-02-13 | ↗ |
| 21 | IV-C, | 652.3K | 2.30% | 652.3K | — | 652.3K | — | PN | — | 2023-02-09 | ↗ |
| 22 | Clarus IV Galera Royalty AIV, L.P. | 550.7K | 1.90% | 550.7K | — | 550.7K | — | PN | — | 2023-02-09 | ↗ |
| 23 | IV-A, | 542.6K | 1.90% | 542.6K | — | 542.6K | — | PN | — | 2023-02-09 | ↗ |
| 24 | IV-B, | 353.7K | 1.20% | 353.7K | — | 353.7K | — | PN | — | 2023-02-09 | ↗ |
| 25 | IV-D, | 130.4K | 0.50% | 130.4K | — | 130.4K | — | PN | — | 2023-02-09 | ↗ |
Institutional Activity (13F)
Institutional ownership trend
From
To
13F snapshot — 2026 Q1
Investors holding
1
+1 vs prev Q
New positions
1
Closed positions
0
Increased
1
Reduced
0
Put/Call ratio
0.00
Calls held
—
Puts held
—
Top institutional holders
| # | Investor | Shares / Δ | Mkt value / Δ | Own% / Δ | Weight% / Δ | Avg px / Perf. | Hold / Status |
|---|---|---|---|---|---|---|---|
| 1 | GOLDEN STATE EQUITY PARTNERS | 93.00 +93.0 (+100.0%) | 4.00 +4.0 (+100.0%) | 0.00% +0.000 pp | 0.00% +0.000 pp | USD0.04 +25.0% | 1 qtrs NEW |
Ownership breakdown by holder
ETF Ownership
Top ETFs holding this stock
This company is not held by any ETF in our universe.
Insider Activity
Insider Activity — Latest Quarter
Ratio by transactions
0.00
Bearish
Buys
4
Sells
0
Shares acquired
288.0K
Shares disposed
—
Cash buys
—
Cash sales
—
Net activity
+288,000
Insider buys vs sells (history)
From
To
Recent insider transactions
From
To
| Date | Person | Role | Transaction | A/D | Security | Shares | Price | Value | Owned after | D/I | Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 2026-04-07 | FRIEDMAN MICHAEL R. | Director | C-Conversion | A | Common Stock | 5,336,870 | 0.00 | — | 5,336,870 | I | ↗ |
| 2026-04-07 | Emerald Bioventures, LLC | 10% Owner | — | — | Common Stock | 0 | 0.00 | — | 40,216,160 | D | ↗ |
| 2026-04-07 | CHANG NANCY T | Director / 10% Owner | C-Conversion | A | Common Stock | 1,180,611 | 0.00 | — | 8,825,543 | D | ↗ |
| 2025-11-20 | Sorensen Mel | Director / Officer | S-Sale | D | Common Stock | 70,000 | 0.02 | 1.4K | 195,029 | D | ↗ |
| 2025-05-01 | Sussman Joel F. | Officer | A-Award | A | Stock Option (Right to Buy) | 2,000,000 | 0.02 | 44.0K | 2,000,000 | D | ↗ |
| 2025-05-01 | Sorensen Mel | Director / Officer | A-Award | A | Stock Option (Right to Buy) | 6,000,000 | 0.02 | 132.0K | 6,000,000 | D | ↗ |
| 2025-02-24 | LOKAY KEVIN G | Director | A-Award | A | Stock Option (Right to Buy) | 48,000 | 0.04 | 2.0K | 48,000 | D | ↗ |
| 2025-02-24 | FRIEDMAN MICHAEL R. | Director | A-Award | A | Stock Option (Right to Buy) | 96,000 | 0.04 | 3.9K | 96,000 | D | ↗ |
| 2025-02-24 | CHANG NANCY T | Director / 10% Owner | A-Award | A | Stock Option (Right to Buy) | 96,000 | 0.04 | 3.9K | 96,000 | D | ↗ |
| 2025-02-24 | Alleva Lawrence M | Director | A-Award | A | Stock Option (Right to Buy) | 48,000 | 0.04 | 2.0K | 48,000 | D | ↗ |
| 2024-12-30 | FRIEDMAN MICHAEL R. | — | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2024-12-30 | CHANG NANCY T | — | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2024-08-16 | Sorensen Mel | Director / Officer | S-Sale | D | Common Stock | 67,015 | 0.07 | 4.8K | 265,029 | — | ↗ |
| 2024-04-19 | Schneid Yair | 10% Owner | P-Purchase | A | Common Stock | 99,371 | 0.19 | 19.3K | 10,823,610 | — | ↗ |
| 2024-04-18 | Schneid Yair | 10% Owner | P-Purchase | A | Common Stock | 74,202 | 0.20 | 14.8K | 10,723,610 | — | ↗ |
| 2024-04-17 | Schneid Yair | 10% Owner | P-Purchase | A | Common Stock | 241,028 | 0.20 | 48.2K | 8,770,805 | — | ↗ |
| 2024-04-16 | Soffer Rochel | 10% Owner | — | I | Common Stock | 0 | 0.00 | — | 2,750,000 | — | ↗ |
| 2024-02-08 | Schneid Yair | 10% Owner | P-Purchase | A | Common Stock | 150,000 | 0.17 | 25.7K | 8,043,203 | — | ↗ |
| 2024-02-07 | Schneid Yair | 10% Owner | P-Purchase | A | Common Stock | 150,000 | 0.17 | 25.9K | 7,893,203 | — | ↗ |
| 2024-02-06 | Schneid Yair | 10% Owner | P-Purchase | A | Common Stock | 25,000 | 0.20 | 5.0K | 7,718,203 | — | ↗ |
| 2024-02-05 | Schneid Yair | 10% Owner | P-Purchase | A | Common Stock | 97,402 | 0.18 | 17.9K | 7,693,203 | — | ↗ |
| 2024-01-30 | Schneid Yair | 10% Owner | P-Purchase | A | Common Stock | 335,000 | 0.18 | 60.6K | 7,595,801 | — | ↗ |
| 2024-01-29 | Schneid Yair | 10% Owner | P-Purchase | A | Common Stock | 150,000 | 0.18 | 27.0K | 7,260,801 | — | ↗ |
| 2024-01-05 | Schneid Yair | 10% Owner | — | D | Common Stock | 0 | 0.00 | — | 7,110,801 | — | ↗ |
| 2023-12-31 | Altamont Pharmaceutical Holdings, LLC | 10% Owner | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2023-10-31 | Altamont Pharmaceutical Holdings, LLC | 10% Owner | — | I | Common Stock | 0 | 0.00 | — | 5,280,000 | — | ↗ |
| 2023-07-01 | West Linda | Director | A-Award | A | Stock Option (Right to Buy) | 23,382 | 3.12 | 73.0K | 23,382 | — | ↗ |
| 2023-07-01 | Alleva Lawrence M | Director | A-Award | A | Stock Option (Right to Buy) | 22,762 | 3.12 | 71.0K | 22,762 | — | ↗ |
| 2023-06-14 | West Linda | Director | A-Award | A | Stock Option (Right to Buy) | 48,000 | 3.27 | 157.0K | 48,000 | — | ↗ |
| 2023-06-14 | POWELL MICHAEL | Director | A-Award | A | Stock Option (Right to Buy) | 64,000 | 3.27 | 209.3K | 64,000 | — | ↗ |
| 2023-06-14 | LOKAY KEVIN G | Director | A-Award | A | Stock Option (Right to Buy) | 48,000 | 3.27 | 157.0K | 48,000 | — | ↗ |
| 2023-06-14 | Cunningham Emmett | Director | A-Award | A | Stock Option (Right to Buy) | 48,000 | 3.27 | 157.0K | 0 | — | ↗ |
| 2023-06-14 | Alleva Lawrence M | Director | A-Award | A | Stock Option (Right to Buy) | 48,000 | 3.27 | 157.0K | 48,000 | — | ↗ |
| 2023-03-16 | Bachleda Mark | Officer | P-Purchase | A | Common Stock | 11,000 | 2.25 | 24.7K | 11,000 | — | ↗ |
| 2023-03-13 | Degnan Chris | Officer | P-Purchase | A | Common Stock | 10,000 | 1.96 | 19.6K | 10,000 | — | ↗ |
| 2023-03-10 | Sorensen Mel | Director / Officer | P-Purchase | A | Common Stock | 100,000 | 1.68 | 168.1K | 332,044 | — | ↗ |
| 2023-02-25 | Stacey Jennifer Evans | Officer | A-Award | A | Stock Option (Right to Buy) | 135,000 | 1.78 | 240.3K | 135,000 | — | ↗ |
| 2023-02-25 | Sorensen Mel | Director / Officer | A-Award | A | Stock Option (Right to Buy) | 440,000 | 1.78 | 783.2K | 440,000 | — | ↗ |
| 2023-02-25 | Kennedy Eugene P. | Officer | A-Award | A | Stock Option (Right to Buy) | 55,000 | 1.78 | 97.9K | 55,000 | — | ↗ |
| 2023-02-25 | Degnan Chris | Officer | A-Award | A | Stock Option (Right to Buy) | 185,000 | 1.78 | 329.3K | 185,000 | — | ↗ |
| 2023-02-25 | Beardsley Robert A | Officer | A-Award | A | Stock Option (Right to Buy) | 135,000 | 1.78 | 240.3K | 135,000 | — | ↗ |
| 2023-02-25 | Bachleda Mark | Officer | A-Award | A | Stock Option (Right to Buy) | 135,000 | 1.78 | 240.3K | 135,000 | — | ↗ |
| 2022-11-21 | Beardsley Robert A | Officer | M-Exempt | D | Stock Option | 10,000 | 0.00 | — | 75,651 | — | ↗ |
| 2022-09-01 | Kennedy Eugene P. | Officer | A-Award | A | Stock Option (Right to Buy) | 150,000 | 1.29 | 193.5K | 150,000 | — | ↗ |
| 2022-07-18 | Alleva Lawrence M | Director | G-Gift | D | Common Stock | 4,000 | 0.00 | — | 2,325 | — | ↗ |
| 2022-07-01 | West Linda | Director | A-Award | A | Stock Option (Right to Buy) | 58,496 | 1.29 | 75.5K | 58,496 | — | ↗ |
| 2022-06-15 | West Linda | Director | A-Award | A | Stock Option (Right to Buy) | 15,000 | 0.00 | — | 15,000 | — | ↗ |
| 2022-06-15 | POWELL MICHAEL | Director | A-Award | A | Stock Option (Right to Buy) | 20,000 | 0.00 | — | 20,000 | — | ↗ |
| 2022-06-15 | LOKAY KEVIN G | Director | A-Award | A | Stock Option (Right to Buy) | 15,000 | 0.00 | — | 15,000 | — | ↗ |
| 2022-06-15 | Cunningham Emmett | Director | A-Award | A | Stock Option (Right to Buy) | 15,000 | 0.00 | — | 0 | — | ↗ |
| 2022-06-15 | Alleva Lawrence M | Director | A-Award | A | Stock Option (Right to Buy) | 15,000 | 0.00 | — | 15,000 | — | ↗ |
| 2022-02-28 | Stacey Jennifer Evans | Officer | A-Award | A | Stock Option (Right to Buy) | 75,000 | 2.24 | 168.0K | 75,000 | — | ↗ |
| 2022-02-28 | Sorensen Mel | Director / Officer | A-Award | A | Stock Option (Right to Buy) | 264,400 | 2.24 | 592.3K | 264,400 | — | ↗ |
| 2022-02-28 | HOLMLUND JON T | Officer | A-Award | A | Stock Option (Right to Buy) | 75,000 | 2.24 | 168.0K | 75,000 | — | ↗ |
| 2022-02-28 | Degnan Chris | Officer | A-Award | A | Stock Option (Right to Buy) | 135,000 | 2.24 | 302.4K | 135,000 | — | ↗ |
| 2022-02-28 | Beardsley Robert A | Officer | A-Award | A | Stock Option (Right to Buy) | 75,000 | 2.24 | 168.0K | 75,000 | — | ↗ |
| 2022-02-28 | Bachleda Mark | Officer | A-Award | A | Stock Option (Right to Buy) | 75,000 | 2.24 | 168.0K | 75,000 | — | ↗ |
| 2021-12-17 | West Linda | Director | P-Purchase | A | Common Stock | 20,000 | 2.74 | 54.8K | 60,000 | — | ↗ |
| 2021-12-17 | Beardsley Robert A | Officer | M-Exempt | D | Stock Option | 20,000 | 1.07 | 21.4K | 95,651 | — | ↗ |
| 2021-10-08 | Stacey Jennifer Evans | Officer | A-Award | A | Stock Option (Right to Buy) | 130,000 | 7.84 | 1.02M | 130,000 | — | ↗ |
| 2021-10-08 | Bachleda Mark | Officer | A-Award | A | Stock Option (Right to Buy) | 200,000 | 7.84 | 1.57M | 200,000 | — | ↗ |
| 2021-09-01 | HOLMLUND JON T | Officer | M-Exempt | A | Common Stock | 47,756 | 2.43 | 116.0K | 47,756 | — | ↗ |
| 2021-07-01 | West Linda | Director | A-Award | A | Stock Option (Right to Buy) | 8,730 | 10.09 | 88.1K | 8,730 | — | ↗ |
| 2021-07-01 | Cunningham Emmett | Director | A-Award | A | Stock Option (Right to Buy) | 5,408 | 10.09 | 54.6K | 0 | — | ↗ |
| 2021-07-01 | Alleva Lawrence M | Director | A-Award | A | Stock Option (Right to Buy) | 8,498 | 10.09 | 85.7K | 8,498 | — | ↗ |
| 2021-06-16 | West Linda | Director | A-Award | A | Stock Option (Right to Buy) | 9,888 | 8.90 | 88.0K | 9,888 | — | ↗ |
| 2021-06-16 | POWELL MICHAEL | Director | A-Award | A | Stock Option (Right to Buy) | 13,179 | 8.90 | 117.3K | 13,179 | — | ↗ |
| 2021-06-16 | LOKAY KEVIN G | Director | A-Award | A | Stock Option (Right to Buy) | 9,888 | 8.90 | 88.0K | 9,888 | — | ↗ |
| 2021-06-16 | Cunningham Emmett | Director | A-Award | A | Stock Option (Right to Buy) | 9,888 | 8.90 | 88.0K | 0 | — | ↗ |
| 2021-06-16 | Alleva Lawrence M | Director | A-Award | A | Stock Option (Right to Buy) | 9,888 | 8.90 | 88.0K | 9,888 | — | ↗ |
| 2021-06-15 | West Linda | Director | P-Purchase | A | Common Stock | 10,000 | 9.13 | 91.3K | 40,000 | — | ↗ |
| 2021-06-02 | West Linda | Director | P-Purchase | A | Common Stock | 10,000 | 8.65 | 86.5K | 30,000 | — | ↗ |
| 2021-06-01 | West Linda | Director | P-Purchase | A | Common Stock | 10,000 | 8.64 | 86.4K | 20,000 | — | ↗ |
| 2021-06-01 | Alleva Lawrence M | Director | P-Purchase | A | Common Stock | 4,045 | 8.59 | 34.7K | 4,045 | — | ↗ |
| 2021-05-28 | West Linda | Director | P-Purchase | A | Common Stock | 10,000 | 8.64 | 86.4K | 10,000 | — | ↗ |
| 2021-03-26 | Sorensen Mel | Director / Officer | M-Exempt | A | Common Stock | 46,940 | 1.14 | 53.5K | 232,044 | — | ↗ |
| 2021-02-18 | Novo Holdings A/S | 10% Owner | S-Sale | D | COMMON STOCK | 500,000 | 10.58 | 5.29M | 2,459,021 | — | ↗ |
| 2021-01-26 | Sussman Joel F. | Officer | A-Award | A | Stock Option (Right to Buy) | 50,000 | 11.99 | 599.5K | 50,000 | — | ↗ |
| 2021-01-26 | Sorensen Mel | Director / Officer | A-Award | A | Stock Option (Right to Buy) | 190,000 | 11.99 | 2.28M | 190,000 | — | ↗ |
| 2021-01-26 | HOLMLUND JON T | Officer | A-Award | A | Stock Option (Right to Buy) | 71,250 | 11.99 | 854.3K | 71,250 | — | ↗ |
| 2021-01-26 | Fratamico Arthur | Officer | A-Award | A | Stock Option (Right to Buy) | 75,000 | 11.99 | 899.3K | 75,000 | — | ↗ |
| 2021-01-26 | Degnan Chris | Officer | A-Award | A | Stock Option (Right to Buy) | 82,500 | 11.99 | 989.2K | 82,500 | — | ↗ |
| 2021-01-26 | Beardsley Robert A | Officer | A-Award | A | Stock Option (Right to Buy) | 75,000 | 11.99 | 899.3K | 75,000 | — | ↗ |
| 2020-11-13 | Sussman Joel F. | Officer | M-Exempt | D | Stock Option (Right to Buy) | 2,639 | 2.43 | 6.4K | 32,238 | — | ↗ |
| 2020-11-13 | Alleva Lawrence M | Director | P-Purchase | A | Common Stock | 2,325 | 10.22 | 23.8K | 6,325 | — | ↗ |
| 2020-11-12 | Sussman Joel F. | Officer | M-Exempt | A | Common Stock | 10,000 | 1.07 | 10.7K | 10,000 | — | ↗ |
| 2020-10-26 | HOLMLUND JON T | Officer | S-Sale | D | Common Stock | 2,244 | 15.00 | 33.7K | 0 | — | ↗ |
| 2020-10-15 | Novo Holdings A/S | 10% Owner | S-Sale | D | COMMON STOCK | 450,000 | 11.00 | 4.95M | 2,959,021 | — | ↗ |
| 2020-10-06 | HOLMLUND JON T | Officer | M-Exempt | A | Common Stock | 4,904 | 1.07 | 5.2K | 4,904 | — | ↗ |
| 2020-10-05 | HOLMLUND JON T | Officer | M-Exempt | D | Stock Option | 100 | 1.07 | 107.00 | 4,904 | — | ↗ |
| 2020-06-19 | Novartis Bioventures Ltd | — | S-Sale | D | Common Stock | 1,001,312 | 8.25 | 8.26M | 2,467,961 | — | ↗ |
| 2020-06-18 | Novartis Bioventures Ltd | — | S-Sale | D | Common Stock | 900 | 9.04 | 8.1K | 3,469,273 | — | ↗ |
| 2020-06-17 | Novartis Bioventures Ltd | 10% Owner | S-Sale | D | Common Stock | 4,622 | 9.27 | 42.8K | 3,470,173 | — | ↗ |
| 2020-06-16 | Novartis Bioventures Ltd | 10% Owner | S-Sale | D | Common Stock | 8,600 | 9.30 | 80.0K | 3,474,795 | — | ↗ |
| 2020-06-15 | Novartis Bioventures Ltd | 10% Owner | S-Sale | D | Common Stock | 6,164 | 9.05 | 55.8K | 3,483,395 | — | ↗ |
| 2020-06-12 | Novartis Bioventures Ltd | 10% Owner | S-Sale | D | Common Stock | 1,500 | 9.19 | 13.8K | 3,489,559 | — | ↗ |
| 2020-06-11 | Novartis Bioventures Ltd | 10% Owner | S-Sale | D | Common Stock | 7,200 | 9.21 | 66.3K | 3,491,059 | — | ↗ |
| 2020-06-10 | Novartis Bioventures Ltd | 10% Owner | S-Sale | D | Common Stock | 8,532 | 9.46 | 80.7K | 3,498,259 | — | ↗ |
| 2020-06-09 | POWELL MICHAEL | Director / 10% Owner | A-Award | A | Stock Option (Right to Buy) | 13,179 | 9.31 | 122.7K | 13,179 | — | ↗ |
| 2020-06-09 | Novartis Bioventures Ltd | 10% Owner | S-Sale | D | Common Stock | 7,000 | 9.38 | 65.7K | 3,506,791 | — | ↗ |
| 2020-06-09 | LOKAY KEVIN G | Director | A-Award | A | Stock Option (Right to Buy) | 9,888 | 9.31 | 92.1K | 9,888 | — | ↗ |
| 2020-06-09 | Cunningham Emmett | Director | A-Award | A | Stock Option (Right to Buy) | 9,888 | 9.31 | 92.1K | 0 | — | ↗ |
| 2020-06-09 | Alleva Lawrence M | Director | A-Award | A | Stock Option (Right to Buy) | 9,888 | 9.31 | 92.1K | 9,888 | — | ↗ |
| 2020-06-08 | Novartis Bioventures Ltd | 10% Owner | S-Sale | D | Common Stock | 5,659 | 9.66 | 54.7K | 3,513,791 | — | ↗ |
| 2020-06-05 | Novartis Bioventures Ltd | 10% Owner | S-Sale | D | Common Stock | 8,652 | 9.66 | 83.6K | 3,519,450 | — | ↗ |
| 2020-06-04 | Novartis Bioventures Ltd | 10% Owner | S-Sale | D | Common Stock | 4,088 | 9.55 | 39.0K | 3,528,102 | — | ↗ |
| 2020-06-03 | Novartis Bioventures Ltd | 10% Owner | S-Sale | D | Common Stock | 5,208 | 9.78 | 50.9K | 3,532,190 | — | ↗ |
| 2020-06-02 | Novartis Bioventures Ltd | 10% Owner | S-Sale | D | Common Stock | 5,669 | 9.68 | 54.9K | 3,537,398 | — | ↗ |
| 2020-05-26 | HOLMLUND JON T | Officer | M-Exempt | A | Common Stock | 692 | 1.07 | 740.44 | 692 | — | ↗ |
| 2020-05-21 | HOLMLUND JON T | Officer | M-Exempt | D | Stock Option | 1,174 | 1.07 | 1.3K | 5,696 | — | ↗ |
| 2020-05-20 | HOLMLUND JON T | Officer | M-Exempt | D | Stock Option | 969 | 1.07 | 1.0K | 6,870 | — | ↗ |
| 2020-05-12 | HOLMLUND JON T | Officer | M-Exempt | A | Common Stock | 671 | 1.07 | 717.97 | 671 | — | ↗ |
| 2020-05-11 | HOLMLUND JON T | Officer | M-Exempt | D | Stock Option | 185 | 1.07 | 197.95 | 8,510 | — | ↗ |
| 2020-05-08 | HOLMLUND JON T | Officer | M-Exempt | A | Common Stock | 5,102 | 1.07 | 5.5K | 5,102 | — | ↗ |
| 2020-05-07 | HOLMLUND JON T | Officer | M-Exempt | D | Stock Option | 2,059 | 1.07 | 2.2K | 13,797 | — | ↗ |
| 2020-05-06 | HOLMLUND JON T | Officer | M-Exempt | D | Stock Option | 1,489 | 1.07 | 1.6K | 15,856 | — | ↗ |
| 2020-05-05 | HOLMLUND JON T | Officer | M-Exempt | D | Stock Option | 3,064 | 1.07 | 3.3K | 17,345 | — | ↗ |
| 2020-03-31 | West Linda | Director | A-Award | A | Stock Option (Right to Buy) | 19,776 | 9.50 | 187.9K | 19,776 | — | ↗ |
| 2020-01-31 | Sussman Joel F. | Officer | A-Award | A | Stock Option (Right to Buy) | 49,263 | 14.84 | 731.1K | 49,623 | — | ↗ |
| 2020-01-31 | Sorensen Mel | Director / Officer | A-Award | A | Stock Option (Right to Buy) | 186,087 | 14.84 | 2.76M | 186,087 | — | ↗ |
| 2020-01-31 | Riley Dennis | Officer | A-Award | A | Stock Option (Right to Buy) | 74,435 | 14.84 | 1.10M | 74,435 | — | ↗ |
| 2020-01-31 | HOLMLUND JON T | Officer | A-Award | A | Stock Option (Right to Buy) | 74,435 | 14.84 | 1.10M | 74,435 | — | ↗ |
| 2020-01-31 | Fratamico Arthur | Officer | A-Award | A | Stock Option (Right to Buy) | 74,435 | 14.84 | 1.10M | 74,435 | — | ↗ |
| 2020-01-31 | Degnan Chris | Officer | A-Award | A | Stock Option (Right to Buy) | 74,435 | 14.84 | 1.10M | 74,435 | — | ↗ |
| 2020-01-31 | Beardsley Robert A | Officer | A-Award | A | Stock Option (Right to Buy) | 74,435 | 14.84 | 1.10M | 74,435 | — | ↗ |
| 2019-12-13 | Alleva Lawrence M | Director | P-Purchase | A | Common Stock | 4,000 | 9.78 | 39.1K | 4,000 | — | ↗ |
| 2019-11-12 | Sofinnova Venture Partners IX, L.P. | 10% Owner | P-Purchase | A | Common Stock | 750,000 | 12.00 | 9.00M | 3,083,712 | — | ↗ |
| 2019-11-12 | Novo Holdings A/S | 10% Owner | C-Conversion | D | SERIES B PREFERRED STOCK | 12,000,000 | 0.00 | — | 0 | — | ↗ |
| 2019-11-12 | Novartis Bioventures Ltd | 10% Owner | C-Conversion | D | Series A Preferred Stock | 9,000,000 | 0.00 | — | 0 | — | ↗ |
| 2019-11-12 | New Enterprise Associates 14, L.P. | 10% Owner | C-Conversion | D | Series C Preferred Stock | 1,354,829 | 0.00 | — | 0 | — | ↗ |
| 2019-11-12 | Clarus IV-A, L.P. | 10% Owner | C-Conversion | A | Common Stock | 555,193 | 0.00 | — | 555,193 | — | ↗ |
| 2019-11-12 | Blackstone Clarus GP L.P. | 10% Owner | P-Purchase | A | Common Stock | 97,131 | 12.00 | 1.17M | 652,324 | — | ↗ |
| 2019-11-12 | Beardsley Robert A | Officer | C-Conversion | A | Common Stock | 15,361 | 0.00 | — | 68,191 | — | ↗ |
| 2019-11-06 | Wood Brian | 10% Owner | — | D | Stock Option | 20,409 | 1.07 | 21.8K | 0 | — | ↗ |
| 2019-11-06 | Sussman Joel F. | Officer | — | D | Stock Option | 34,877 | 2.43 | 84.8K | 0 | — | ↗ |
| 2019-11-06 | Sorensen Mel | Director / Officer | — | D | Stock Option | 88,710 | 2.68 | 237.7K | 0 | — | ↗ |
| 2019-11-06 | Sofinnova Venture Partners IX, L.P. | 10% Owner | — | D | Series B-2 Preferred Stock | 1,797,843 | 0.00 | — | 0 | — | ↗ |
| 2019-11-06 | Schall Otto | 10% Owner | — | D | Stock Option | 1,977 | 7.08 | 14.0K | 0 | — | ↗ |
| 2019-11-06 | Ross Stephen A | 10% Owner | — | D | Stock Option | 41,981 | 2.43 | 102.0K | 0 | — | ↗ |
| 2019-11-06 | Riley Dennis | 10% Owner | — | D | Stock Option | 21,793 | 1.14 | 24.8K | 0 | — | ↗ |
| 2019-11-06 | POWELL MICHAEL | Director / 10% Owner | A-Award | A | Stock Option | 19,776 | 12.00 | 237.3K | 19,776 | — | ↗ |
| 2019-11-06 | Novo Holdings A/S | 10% Owner | — | D | SERIES C PREFERRED STOCK | 535,869 | 0.00 | — | 0 | — | ↗ |
| 2019-11-06 | Novartis Bioventures Ltd | 10% Owner | — | I | Series B Preferred Stock | 1,423,891 | 0.00 | — | 0 | — | ↗ |
| 2019-11-06 | New Enterprise Associates 14, L.P. | 10% Owner | — | D | Series A Preferred Stock | 1,774,922 | 0.00 | — | 0 | — | ↗ |
| 2019-11-06 | Matthes Catherine L. | 10% Owner | — | D | Stock Option | 8,503 | 1.07 | 9.1K | 0 | — | ↗ |
| 2019-11-06 | LOKAY KEVIN G | Director | — | D | Stock Option | 19,776 | 9.26 | 183.1K | 0 | — | ↗ |
| 2019-11-06 | Keene Jeffrey | 10% Owner | — | D | Series A Preferred Stock | 17,582 | 0.00 | — | 0 | — | ↗ |
| 2019-11-06 | HOLMLUND JON T | Officer | — | D | Stock Option | 20,409 | 1.07 | 21.8K | 0 | — | ↗ |
| 2019-11-06 | Fuller Jason | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2019-11-06 | Fratamico Arthur | Officer | — | D | Stock Option | 43,507 | 7.08 | 308.0K | 0 | — | ↗ |
| 2019-11-06 | Degnan Chris | Officer | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2019-11-06 | Cunningham Emmett | Director | — | — | — | 0 | 0.00 | — | 0 | — | ↗ |
| 2019-11-06 | Clarus IV-A, L.P. | 10% Owner | — | I | Series C Redeemable Convertible Preferred Stock | 561,385 | 0.00 | — | 0 | — | ↗ |
| 2019-11-06 | Buckler Regina A. | 10% Owner | — | D | Series A Preferred Stock | 7,996 | 0.00 | — | 0 | — | ↗ |
| 2019-11-06 | Brill Jeffrey | 10% Owner | — | D | Stock Option | 8,285 | 2.68 | 22.2K | 0 | — | ↗ |
| 2019-11-06 | Blackstone Group Inc | 10% Owner | J-Other | A | Stock Options (Right to Buy) | 19,776 | 12.00 | 237.3K | 0 | — | ↗ |
| 2019-11-06 | Blackstone Clarus GP L.P. | 10% Owner | — | I | Series C Redeemable Convertible Preferred Stock | 561,385 | 0.00 | — | 0 | — | ↗ |
| 2019-11-06 | Beardsley Robert A | Officer | — | D | Stock Option | 34,383 | 2.68 | 92.1K | 0 | — | ↗ |
| 2019-11-06 | Alleva Lawrence M | Director | — | D | Stock Option | 19,776 | 9.61 | 190.0K | 0 | — | ↗ |
| 2014-04-17 | Schneid Yair | 10% Owner | P-Purchase | A | Common Stock | 318,150 | 0.19 | 60.4K | 8,361,353 | — | ↗ |
Executive team
Top executives
Shares Outstanding
75.89M
Executive compensation
Executive compensation (annual)
| # | Year | Executive | Salary | Bonus | Stock award | Option award | Incentive | Other | Total | % Stock- based |
Filing |
|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 2025 | J. Mel Sorensen, M.D., President and Chief Executive Officer | 619.5K | — | — | 114.3K | — | 14.0K | 747.8K | 15.29% | ↗ |
| 2 | 2025 | Joel Sussman Chief Accounting Officer, Treasurer and Secretary | 336.0K | 20.0K | — | 38.1K | — | 14.0K | 408.1K | 9.34% | ↗ |
| 3 | 2024 | J. Mel Sorensen, M.D., President and Chief Executive Officer | 619.5K | — | — | — | — | 13.8K | 633.3K | 0.00% | ↗ |
| 4 | 2024 | Joel Sussman Chief Accounting Officer, Treasurer and Secretary | 336.0K | — | — | — | — | 13.4K | 349.4K | 0.00% | ↗ |
| 5 | 2023 | J. Mel Sorensen, M.D., President and Chief Executive Officer | 616.5K | — | — | 617.6K | — | 16.1K | 1.25M | 49.40% | ↗ |
| 6 | 2023 | Christopher Degnan, Former Chief Financial Officer | 460.8K | — | — | 259.7K | — | 13.2K | 733.7K | 35.39% | ↗ |
| 7 | 2023 | Mark Bachleda, Pharm.D., former Chief Commercial Officer | 310.0K | — | — | 189.5K | — | 211.8K | 711.3K | 26.64% | ↗ |
| 8 | 2023 | Robert A. Beardsley, Ph.D., Former Chief Operating Officer | 451.4K | — | — | 189.5K | — | 13.2K | 654.1K | 28.97% | ↗ |
| 9 | 2022 | J. Mel Sorensen, M.D., President and Chief Executive Officer | 596.9K | — | — | 453.1K | 295.4K | 16.0K | 1.36M | 33.28% | ↗ |
| 10 | 2022 | Christopher Degnan, Former Chief Financial Officer | 432.3K | — | — | 231.3K | 159.1K | 12.2K | 834.9K | 27.71% | ↗ |
| 11 | 2022 | Christopher Degnan, Chief Financial Officer | 432.3K | — | — | 231.3K | 159.1K | 12.2K | 834.9K | 27.71% | ↗ |
| 12 | 2022 | Mark Bachleda, Pharm.D., Chief Commercial Officer | 475.0K | — | — | 128.5K | 172.9K | 12.2K | 788.6K | 16.30% | ↗ |
| 13 | 2022 | Mark Bachleda, Pharm.D., former Chief Commercial Officer | 475.0K | — | — | 128.5K | 172.9K | 12.2K | 788.6K | 16.30% | ↗ |
| 14 | 2022 | Robert A. Beardsley, Ph.D., Former Chief Operating Officer | 446.2K | — | — | 128.5K | 171.4K | 11.2K | 757.2K | 16.97% | ↗ |
| 15 | 2021 | J. Mel Sorensen, M.D., President and Chief Executive Officer | 568.4K | — | — | 1.71M | 240.7K | 11.6K | 2.53M | 67.62% | ↗ |
| 16 | 2021 | Mark Bachleda, Pharm.D., Chief Commercial Officer | 109.9K | — | — | 1.14M | 33.9K | 3.0K | 1.29M | 88.61% | ↗ |
| 17 | 2021 | Christopher Degnan, Chief Financial Officer | 395.8K | — | — | 744.2K | 121.9K | 11.6K | 1.27M | 58.43% | ↗ |
| 18 | 2020 | J. Mel Sorensen, M.D., President and Chief Executive Officer | 545.7K | — | — | 2.06M | 345.2K | 11.4K | 2.96M | 69.50% | ↗ |
| 19 | 2020 | Christopher Degnan, Chief Financial Officer | 380.0K | 70.0K | — | 822.4K | 174.8K | 11.4K | 1.46M | 56.38% | ↗ |
| 20 | 2020 | Robert A. Beardsley, Ph.D., Chief Operating Officer | 422.0K | — | — | 822.4K | 194.1K | 11.4K | 1.45M | 56.72% | ↗ |
| 21 | 2019 | J. Mel Sorensen, M.D., President and Chief Executive Officer | 431.6K | — | — | 1.89M | 139.7K | — | 2.47M | 76.82% | ↗ |
| 22 | 2019 | Christopher Degnan, Chief Financial Officer | 76.5K | 70.0K | — | 2.06M | 23.3K | — | 2.23M | 92.39% | ↗ |
| 23 | 2019 | Robert A. Beardsley, Ph.D., Chief Operating Officer | 358.5K | — | — | 1.21M | 97.6K | — | 1.67M | 72.66% | ↗ |
| 24 | 2018 | J. Mel Sorensen, M.D., President and Chief Executive Officer | 386.4K | — | — | — | 135.2K | — | 521.6K | 0.00% | ↗ |
| 25 | 2018 | Robert A. Beardsley, Ph.D., Chief Operating Officer | 325.7K | — | — | — | 97.7K | — | 423.4K | 0.00% | ↗ |
CEO compensation breakdown
Proxy statements
Proxy statements (DEF 14A)
Recent SEC filings
Executive team
| Name | Title | Compensation | Gender |
|---|---|---|---|
| J. Mel Sorensen | Chief Executive Officer, President & Chairman | 633.5K | — |
| Joel F. Sussman | Chief Accounting Officer, Secretary & Treasurer | 370.0K | male |
ESG Rating
ESG Score History BIOTECHNOLOGY
Benchmark vs Sector
Senate Trading Activity
No Senate trading activity found for this company.
House Trading Activity
No House trading activity found for this company.
Market share among peers
Peer comparison — filtered group (TTM)
Your opinion
Share your view on this stock and instantly see how the community has voted over the last 6 months.
Community Opinion for GRTX
Short-term intention
Target Price Distribution
These are community opinions and do not constitute buy or sell advice to act on. The results shown are based on aggregated opinions and are not an investment recommendation, nor do they intend to influence any investment decision.
